Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models
Source abstract
Abstract
While accessing tumor neoantigens and developing effective delivery systems have posed significant challenges in therapeutic oncology vaccines, this study introduces a cost- and time-efficient personalized tumor vaccine demonstrating potent anti-tumor effects in a mouse xenograft model. This vaccine utilizes a lipid nanoparticle (C5 LNP) system loaded with membrane protein antigens (mAg) derived from surgically excised tumor tissue. Its safety and efficacy were validated in a B16-OVA murine model. C5/OVA exhibited significant uptake by dendritic cells (DCs), leading to cross-presentation, maturation, and subsequent initiation of robust cell-mediated and humoral immune responses. This resulted in clear tumor growth suppression and extended survival in the B16-OVA model. Furthermore, the personalized C5/mAg vaccine effectively inhibited tumor growth in a colorectal carcinoma model. When combined with anti-PD-1 therapy, it notably increased complete remission (CR) rates in the CT26 xenograft model. Vaccinated mice demonstrated 100 % resistance to tumor rechallenge, underscoring the vaccine's ability to induce long-term immune memory. This study presents a promising personalized cancer vaccine delivery system with potential for both treatment and prevention of carcinoma in clinical applications. STATEMENT OF SIGNIFICANCE: In this paper, we present a scheme for manufacturing personalized tumor vaccines. The vaccine component consists of lipid nanoparticles (LNPs) designated C5 and membrane protein antigens (mAg) derived from autologous tumor tissue surgically resected from the patient. Our study demonstrates that the personalized mAg-C5 vaccine for colorectal carcinoma significantly inhibits tumor growth. Furthermore, conjugation with anti-PD-1 therapy demonstrably increased the complete remission (CR) rate in the murine CT26 xenograft tumor model. Additionally, mice treated with the C5/mAg vaccine exhibited 100 % resistance to tumor growth in a colon carcinoma rechallenge model, indicating the induction of immune memory by the vaccine. Our research results suggest that the mAg-LNP vaccine is a simple, cost-effective treatment that clinicians can easily and quickly integrate into routine practice.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Colorectal cancer tissue-originated spheroids reveal tumor intrinsic signaling pathways and mimic patient clinical chemotherapeutic response as a rapid and valid model10.1016/j.biopha.2023.115585 ↗
3. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates10.1200/JCO.22.02270 ↗
4. Immunotherapy in colorectal cancer: current achievements and future perspective10.7150/ijbs.64077 ↗
5. Therapeutic cancer vaccines: advancements, challenges, and prospects10.1038/s41392-023-01674-3 ↗
6. Construction and application of adenoviral vectors
7. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases10.1038/s41392-023-01408-5 ↗
8. Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy10.1056/NEJMoa2307798 ↗
9. Identification of neoantigens for individualized therapeutic cancer vaccines10.1038/s41573-021-00387-y ↗
10. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma10.1186/s12951-022-01397-7 ↗
11. Neoantigens in cancer immunotherapy
12. An immunogenic personal neoantigen vaccine for patients with melanoma10.1038/nature22991 ↗
13. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer10.1038/nature23003 ↗
14. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer10.1038/s41586-023-06063-y ↗
15. Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation10.3389/fonc.2022.836821 ↗
16. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy10.1038/s41565-020-00781-4 ↗
17. A minimalist binary vaccine carrier for personalized postoperative cancer vaccine therapy10.1002/adma.202109254 ↗
18. Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement10.1021/acsnano.1c04996 ↗
19. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo10.1016/j.jconrel.2019.01.001 ↗
20. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions10.1021/la104590k ↗
21. Modification of the antigenicity of cancer cells by conjugates consisting of hyaluronic acid and foreign antigens10.1039/D3BM00439B ↗
22. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment10.1158/0008-5472.CAN-13-3583 ↗
23. Single-injecting, bioinspired nanocomposite hydrogel that can recruit host immune cells in situ to elicit potent and long-lasting humoral immune responses10.1016/j.biomaterials.2019.119268 ↗
24. Induction of peptide-specific CTL activity and inhibition of tumor growth following immunization with nanoparticles coated with tumor peptide-MHC-I complexes10.4110/in.2021.21.e44 ↗
25. Comparative study of lipid nanoparticle-based mRNA vaccine bioprocess with machine learning and combinatorial artificial neural network-design of experiment approach10.1016/j.ijpharm.2023.123012 ↗
26. Nanoparticle uptake: the phagocyte problem10.1016/j.nantod.2015.06.006 ↗
27. Endosomal escape: a bottleneck for LNP-mediated therapeutics10.1073/pnas.2307800120 ↗
28. Visible light conjugation with triazolinediones as a route to degradable poly(ethylene glycol)-lipids for mRNA lipid nanoparticle formulation10.1002/anie.202301102 ↗
29. Lung cancer immunotherapy: progress, pitfalls, and promises10.1186/s12943-023-01740-y ↗
30. Cancer immunotherapy: moving beyond current vaccines10.1038/nm1100 ↗
31. Neoantigen vaccine delivery for personalized anticancer immunotherapy10.3389/fimmu.2018.01499 ↗
32. COVID-19 vaccine development: milestones, lessons and prospects10.1038/s41392-022-00996-y ↗
33. Lipid nanoparticles in the development of mRNA vaccines for COVID-19
34. Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: a phase 2 randomized study10.1016/j.jvacx.2022.100189 ↗
35. Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects10.1038/s41571-023-00811-9 ↗
36. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering10.1021/acs.nanolett.9b04246 ↗
37. Delivering the messenger: advances in technologies for therapeutic mRNA delivery10.1016/j.ymthe.2019.02.012 ↗
38. Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer10.1073/pnas.2112696119 ↗
39. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation10.1038/s41587-019-0247-3 ↗
40. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
41. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response10.1073/pnas.2207841119 ↗
42. Chapter 7 - tumor-associated antigens
43. Alternative tumour-specific antigens10.1038/s41568-019-0162-4 ↗
44. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma10.1038/s41586-020-2537-9 ↗
45. mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer10.1038/s41541-023-00733-8 ↗
46. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines10.1038/s41571-020-00460-2 ↗
47. Challenges in developing personalized neoantigen cancer vaccines
48. mRNA-based therapeutics: powerful and versatile tools to combat diseases10.1038/s41392-022-01007-w ↗
49. Stimulation of in vivo antitumor immunity with hollow mesoporous silica nanospheres10.1002/anie.201506179 ↗
50. A rapid strategy to develop personalized cancer nanovaccines for different immunogenic tumors
51. Comprehensive mechanism analysis of mesoporous-silica-nanoparticle-induced cancer immunotherapy10.1002/adhm.201501013 ↗